"The last straw"—RFK Jr.'s anti-vaccine ally angrily quits CDC panel after spat
Robert Malone quit a vaccine panel, blaming an HHS spokesperson for "trashing" him.
Signal weather
Stable
The story has moved beyond the first headline and now acts as a reliable context anchor.
One of the federal vaccine advisors hand-selected by anti-vaccine Health Secretary Robert F. Kennedy Jr. has angrily resigned from his position, complaining of "drama" amid a spat with a spokesperson. Robert Malone—a former researcher turned outspoken anti-vaccine activist and conspiracy theorist—confirmed he was stepping down Tuesday afternoon to CQ Roll Call, which first reported the news. He told the outlet that his decision to quit came after a "miscommunication" about the fate of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP). Kennedy had populated ACIP with anti-vaccine allies including Malone, who served as vice chair, after summarily firing all 17 experts on the panel last June. Last week, a federal judge temporarily blocked Kennedy's ACIP appointments, including Malone. He also stayed the changes that its members had made to federal vaccine guidance, as well as the dramatic overhaul of the childhood vaccine schedule Kennedy made without them. The judge ruled all the moves were likely illegal. On Thursday, Malone claimed on social media that the Department of Health and Human Services (HHS) had disbanded ACIP and planned to completely reconstitute it (again), without appealing the judge's ruling or defending Kennedy's ACIP picks from the judge's claims that they were unqualified. But soon after, Malone retracted his claim, saying it was a miscommunication and that disbanding ACIP was merely one of the "options being considered."Read full article Comments
Stay on the signal
Follow "The last straw"—RFK Jr.'s anti-vaccine ally angrily quits CDC panel after spat
Follow this story beyond a single article: new follow-ups, adjacent sources, and the evolving storyline.
Story map
Understand this topic fast
A quick entry into the story: why it matters now, who is involved, and where to go next for context.
Why it matters now
Topic constellation
Open the live map for this story
See which entities, story threads, sources, and follow-up articles shape this story right now.
Click nodes to continue
Entity pages
Story timeline
Continue with this story
A short sequence of events and follow-up stories to understand the arc quickly.
How reliable this looks
Signal and trust for Ars Technica
This source works at a rapid pace: 100% of recent stories land in the hot window, and 0% carry visible search signal.
Reliability
92
Freshness
100
Sources in storyline
1
Related articles
More stories that share tags, source, or category context.
A revolutionary cancer treatment could transform autoimmune disease
Researchers are testing CAR T cell therapy as a way to reset the immune system.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
The US is betting on AI to catch insider trading in prediction markets
The Commodity Futures Trading Commission wants us to know it's taking this very seriously.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
Russia pressures university students to become wartime drone pilots
Universities promise no frontline duty and perks if students enlist in military.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
Anthropic’s $1.5B copyright settlement is getting messy as judge delays approval
Lawyers accused of rushing historic settlement to seize $320 million in fees.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
More from Ars Technica
Fresh reporting and follow-up coverage from the same newsroom.
A revolutionary cancer treatment could transform autoimmune disease
Researchers are testing CAR T cell therapy as a way to reset the immune system.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
The US is betting on AI to catch insider trading in prediction markets
The Commodity Futures Trading Commission wants us to know it's taking this very seriously.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
Russia pressures university students to become wartime drone pilots
Universities promise no frontline duty and perks if students enlist in military.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
Anthropic’s $1.5B copyright settlement is getting messy as judge delays approval
Lawyers accused of rushing historic settlement to seize $320 million in fees.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.